CoChat

Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial

Open access
Hagiwara, Nobuhisa, Kawada-Watanabe, Erisa, Koyanagi, Ryo, Arashi, Hiroyuki, Yamaguchi, Junichi, Nakao, Koichi, Tobaru, Tetsuya, Tanaka, Hiroyuki, Oka, Toshiaki, Endoh, Yasuhiro, Saito, Katsumi, Uchida, Tatsuro, Matsui, Kunihiko, Ogawa, Hiroshi · 2017 · European Heart Journal

The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.

Abstract

AIMS: To elucidate the effects of intensive LDL-C lowering treatment with a standard dose of statin and ezetimibe in patients with dyslipidaemia and high risk of coronary events, targeting LDL-C less than 70 mg/dL (1.8 mmol/L), compared with standard LDL-C lowering lipid monotherapy targeting less than 100 mg/dL (2.6 mmol/L). METHODS AND RESULTS: The HIJ-PROPER study is a prospective, randomized, open-label trial to assess whether intensive LDL-C lowering with standard-dose pitavastatin plus ezetimibe reduces cardiovascular events more than standard LDL-C lowering with pitavastatin monotherapy in patients with acute coronary syndrome (ACS) and dyslipidaemia. Patients were randomized to intensive lowering (target LDL-C < 70 mg/dL [1.8 mmol/L]; pitavastatin plus ezetimibe) or standard lowering (target LDL-C 90 mg/dL to 100 mg/dL [2.3-2.6 mmol/L]; pitavastatin monotherapy). The primary endpoint was a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, unstable angina, and ischaemia-driven revascularization. Between January 2010 and April 2013, 1734 patients were enroled at 19 hospitals in Japan. Patients were followed for at least 36 months. Median follow-up was 3.86 years. Mean follow-up LDL-C was 65.1 mg/dL (1.68 mmol/L) for pitavastatin plus ezetimibe and 84.6 mg/dL (2.19 mmol/L) for pitavastatin monotherapy. LDL-C lowering with statin plus ezetimibe did not reduce primary endpoint occurrence in comparison with standard statin monotherapy (283/864, 32.8% vs. 316/857, 36.9%; HR 0.89, 95% CI 0.76-1.04, P = 0.152). In, ACS patients with higher cholesterol absorption, represented by elevated pre-treatment sitosterol, was associated with significantly lower incidence of the primary endpoint in the statin plus ezetimibe group (HR 0.71, 95% CI 0.56-0.91). CONCLUSION: Although intensive lowering with standard pitavastatin plus ezetimibe showed no more cardiovascular benefit than standard pitavastatin monotherapy in ACS patients with dyslipidaemia, statin plus ezetimibe may be more effective than statin monotherapy in patients with higher cholesterol absorption; further confirmation is needed. TRIAL NO: UMIN000002742, registered as an International Standard Randomized Controlled Trial.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehx162

Cites

52 of 52 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Study flow chart.
Figure 1 Study flow chart.CC BY-NC · PubMed Central
Figure 2 Kaplan–Meier curves for the primary efficacy endpoint and composite of several hard endpoints. (A) Primary endpoint, (B) All-cause death, non-fatal MI, or non-fatal stroke (C) Ischaemia-driven coronary revascularization. MI, myocardial infarction.
Figure 2 Kaplan–Meier curves for the primary efficacy endpoint and composite of several hard endpoints. (A) Primary endpoint, (B) All-cause death, non-fatal MI, or non-fatal stroke (C) Ischaemia-driven coronary revascularization. MI, myocardial infarction.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 52 references

Cited by

See all 139

Metadata

Authors
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., Saito, K., Uchida, T., Matsui, K., & Ogawa, H.
Affiliations
  • Tokyo Women's Medical University (JP)
  • Department of Cardiology, The Heart Institute of Japan, Tokyo Women’s Medical University, 8-1, Kawada-cho, Shinjuku, Tokyo, 162-8666, Japan
  • Division of Cardiology, Cardiovascular Center, Saisei-Kai Kumamoto Hospital, 5-3-1 Chikami, Minami-ku, Kumamoto-shi, Kumamoto 861-4193, Japan
  • Department of Cardiology, Sakakibara Heart Institute, 3-16-1 Asahi-cho, Fuchu-shi, Tokyo 183-0003, Japan
  • Tokyo Metropolitan Tama Medical Center (JP)
  • Seirei Hamamatsu General Hospital (JP)
  • Department of Cardiology, Saisei-Kai Kurihashi Hospital, 714-6 Kouemon, Kuki-shi, Saitama 349-1105, Japan
  • Department of Cardiology, Nishiarai Heart Center, 1-12-8, Nishiarai-honcho, Adachi-Ku, Tokyo 123-0845, Japan
  • Sendai Medical Center (JP)
  • Kumamoto University Hospital (JP)
Corresponding author
Ogawa, Hiroshi
Venue
European Heart Journal
Published
2017-04-18
Volume
38
Issue
29
Pages
2264-2276
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W2606701238
Cited by
136
References
52
Citations by year
2026: 12 · 2025: 12 · 2024: 22 · 2023: 12 · 2022: 14 · 2021: 16 · 2020: 14 · 2019: 16 · 2018: 13 · 2017: 4
FWCI
13.17
Type
journal article
Language
en
Open access
Licence
cc-by-nc
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Lipids, and Metabolism
Keywords
pitavastatin, ezetimibe, LDL cholesterol lowering, acute coronary syndrome, dyslipidemia, intensive lipid-lowering therapy, sitosterol, cholesterol absorption, cardiovascular events, primary prevention, statin monotherapy
MeSH terms
Ezetimibe, ST Elevation Myocardial Infarction, Non-ST Elevated Myocardial Infarction, Aged, Angina, Unstable, Anticholesteremic Agents, Dose-Response Relationship, Drug, Drug Therapy, Combination, Female, Follow-Up Studies, Humans, Cholesterol, LDL, Male, Prospective Studies, Quinolines, Treatment Outcome, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Dyslipidemias, Kaplan-Meier Estimate, Acute Coronary Syndrome

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. https://app.cochat.ai/papers/10.1093/eurheartj/ehx162
The paper
Hagiwara, N., Kawada-Watanabe, E., Koyanagi, R., Arashi, H., Yamaguchi, J., Nakao, K., Tobaru, T., Tanaka, H., Oka, T., Endoh, Y., Saito, K., Uchida, T., Matsui, K., & Ogawa, H. (2017). Low-density lipoprotein cholesterol targeting with pitavastatin + ezetimibe for patients with acute coronary syndrome and dyslipidaemia: the HIJ-PROPER study, a prospective, open-label, randomized trial. European Heart Journal. https://doi.org/10.1093/eurheartj/ehx162

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.